T1	Participants 59 84	breast lymphoscintigraphy
T2	Participants 276 307	patients with breast carcinoma.
T3	Participants 418 443	breast lymphoscintigraphy
T4	Participants 908 933	breast lymphoscintigraphy
T5	Participants 939 1009	control group and experimental group of female breast cancer patients.
